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Abstract: Occupational diseases affect more and more people every year. According to the 
International  Labour  Organization  (ILO),  in  2000  an  estimated  amount  of  at  least  160 
million people became ill as a result of occupational-related hazards or injuries. Globally, 
occupational deaths, diseases and injuries account for an estimated loss of 4% of the Gross 
Domestic  Product.  Important  substances  that  are  related  to  occupational  diseases  are 
isocyanates  and  their  products.  These  substances,  which  are  used  in  a  lot  of  different 
industrial  processes,  are  not  only  toxic  and  irritant,  but  also  allergenic.  Although  the 
exposure to higher concentrations could be monitored and restricted by technical means, 
very  low  concentrations  are  difficult  to  monitor  and  may,  over  time,  lead  to  allergic 
reactions  in  some  workers,  ending  in  an  occupational  disease.  In  order  to  prevent  the 
people from sickening, the mechanisms underlying the disease, by patho-physiological and 
genetical means, have to be known and understood so that high risk groups and early signs 
in  the  development  of  an  allergic  reaction  could  be  detected  before  the  exposure  to 
isocyanates  leads  to  an  occupational  disease.  Therefore,  this  paper  reviews  the  so  
far  known  facts  concerning  the  patho-physiologic  appearance  and  mechanisms  of  
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isocyanate-associated toxic reactions and possible genetic involvement that might trigger 
the allergic reactions. 
Keywords: occupational disease; isocyanate; occupational asthma; pathological findings; 
clinical findings; genetic predisposition 
 
1. Introduction 
Exposure to toxic or irritant substances at workplaces is a health risk and an increasing problem, 
concerning the affected persons on one side and the economic financial sources of the industrialized 
world  on  the  other  side.  In  2000  alone,  according  to  the  International  Labour  
Organization (ILO; www.ilo.org), at least 160 million people became ill as a result of occupationally-
related  hazards  or  injuries.  Globally,  occupational  deaths,  diseases  and  injuries  account  for  an 
estimated loss of 4% of the Gross Domestic Product [1]. Taking only the cases of occupational asthma 
for the United Kingdom in the year 2003 into account, the costs are estimated to reach up to £100 
million. More than half of this is caused by isocyanates [2].  
Occupational asthma (OA) could be divided into a nonimmunological, irritant-induced asthma and 
an immunological, allergy-induced asthma [3-6], which will be addressed in this review. In addition, 
allergy-induced  asthma  can  be  caused  by  two  different  groups  of  agents:  high  molecular  weight 
proteins  (>5,000  Da)  or  low  molecular  weight  agents  (<5,000  Da),  generally  chemicals  like  the 
isocyanates [4-6], as will be discussed herein.  
In occupational disease cases, the affected workers are forced to abandon their jobs, in the worst 
case forever or at least temporarily to recover. Therefore, it is of major concern to recognize possible 
occupational burden and their clinical and morphologic/pathologic signs as early as possible in order to 
avoid the exposure ending in a disease, as in the case of isocyanate-induced asthma, the symptoms 
persist even after cessation of the exposure [7,8]. For many substances dangerous and prescriptive 
limits have been implemented, but a lot of chemical substances are not only toxic or irritant, but could 
also  lead  to  hypersensitivity  reactions.  The  major  problems  are  that:  (1)  these  agents  induce  the 
hypersentitivity  reactions  already  at  very  low  concentrations,  which  technically  are  difficult  to 
monitor, and (2) not all exposed workers are sensitive and develop the disease over time. All this 
together makes it difficult to obtain an effective prophylaxis if the underlying pathological mechanisms 
of  this  allergic  reaction  are  not  completely  understood.  Isocyanates  and  the  large  group  of  its 
derivatives belong to that group of substances which are important in the above mentioned context.  
Isocyanate Occurrence 
Isocyanates  are  very  reactive  chemicals  characterized  by  one  or  more  isocyanate  
groups (─N=C=O). The main reactions of this chemical group are addition reactions with ethanol, 
resulting in urethanes, with amines (resulting in urea derivates) and with water. Here, the product is 
carbamic  acid  which  is  not  stable  and  reacts  further  to  amines,  releasing  free  carbon  dioxide. 
Diisocyanates  and  polyisocyanates  are,  together  with  the  largely  nontoxic  polyol  group,  the  basic Int. J. Environ. Res. Public Health 2011, 8                 
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building  blocks  of  the  polyurethane  (PU)  chemical  industry,  where  they  are  used  solely  or  in 
combination with solvents or additives in the production of adhesives, foams, elastomers, paintings, 
coatings and other materials. 
Since the 1930s the usage of isocyanates has grown rapidly all over the World, reaching millions of 
tons that nowadays are produced and used annually in many different industries, i.e., the car industry, 
aerospace  industry,  metal-working  industry,  wood-working  industry,  mining  and  many  
others [9,10]. Beside of their widespread industrial usage, isocyanates are also more and more used in 
private households, for example in paints or construction foam. 
In generally isocyanates are used as oligo- and polymers. The route of exposure largely depends on 
workplace conditions, especially the given concentration and the temperature during the manufacturing 
process. The exposure occurs mainly by inhalation. Oral incorporation by smoking or eating at the 
workplace or skin exposure are also possible mechanisms [11,12].  
The  current  legal  safety  level  for  isocyanate  concentrations  at  workplaces  in  Germany  
varies  between  0.024  mg/m³  for  methyl  isocyanate  and  up  to  0.054  mg/m³  for  
dicyclohexylmethan-4,4’-diisocyanate, as listed in the attachment to the TRGS (Technische Regel für 
Gefahrstoffe) 430 [13]. In the United Kingdom the workplace exposure limit is 0.02 mg/m³ for all 
isocyanates for an 8 hour time average and 0.07 mg/m³ for a 15 minute short time exposure [14]. 
Diisocyanates at high concentrations can have direct toxic effects on mucous membranes [15] or 
can act at low concentrations as sensitizing agents after binding to different proteins. Concentrations of 
isocyanate as low as 1 ppm has been confirmed to induce significant functional changes in humans and 
inflammation  processes  in  lung  tissues  [16].  In  the  UK  there  is  a  high  incidence  for  OA,  with 
isocyanates being the most common reason [17]. In Germany, more than 50,000 workers are exposed 
to low concentrations of diisocyanates. Between 5% and 25% of these workers may be expected to 
develop  respiratory  disorders  [18-21].  As  the  exposure  can  happen  in  combination  with  different 
solvents and at different concentrations, the monitoring of workplaces might be difficult [10,22]. 
2. Clinical Manifestations after Exposure to Isocyanate 
Clinical symptoms after chemical induced asthma are rarely seen shortly (meaning two to four 
hours) after exposure, but develop after a latency period of some weeks up to months [22]. Exposure to 
methylene  diphenyldiisocyanate  (MDI),  hexamethylene  diisocyanate  (HDI),  and  
toluene-2.4-diisocyanate  (TDI)  can  lead  to  allergic  reactions  with  striking  similarities  to  allergic 
asthma  (type  1)  [10,23].  The  resulting  isocyanate  asthma  accounts  for  the  leading  causes  of 
occupational induced asthma bronchial worldwide. 
After sensitization even very small amounts of isocyanate can induce asthmatic reactions. This and 
other facts, including the aforementioned latency period, the reaction of only a part of the exposed 
workers or the delayed reaction strongly remind one of the classical allergic IgE mediated asthma. 
After  exposure,  up  to  50%  of  the  affected  people  present  with  specific  IgE  or  IgG  antibodies 
depending on the antigen used for antibody detection [10]. Up to now it has been a matter of intense 
debate, if isocyanate asthma really is IgE mediated or IgE independent [20,23,24]. Int. J. Environ. Res. Public Health 2011, 8                 
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2.1. Morphologic Manifestations after Isocyanate Exposure of the Lung 
Morphological changes  in lung epithelium after isocyanate  exposure were described in humans 
(e.g., [8, 25-27]), cell cultures (e.g., [28,29]), and in experimental animal models (e.g., [30-34]). Cell 
culture analyses with human bronchial epithelium cells after exposure to 20 ppb toluene diisocyanate 
(TDI) demonstrate a disintegration of tight junctions between epithelial cells and an increased mucus 
secretion.  No  changes  in  the  motile  cilia  of  the  airway  epithelia  were  seen  at  this  relatively  low 
concentration.  After  incubation  with  increasing  concentrations  of  TDI  (100  ppb  and  500  ppb) 
cumulative damage and impairment of the cilia activity and integrity was visible [28]. The functional 
impairment of the cilia was explained by an interaction between isocyanate and cellular filaments like 
tubulin [28]. 
Pathological  diagnostic  findings  in  isocyanate-induced  asthma  are  mainly  based  on  rare  case 
reports. In low concentrations isocyanates could induce allergic reactions like acute asthma bronchial, 
hypersensitive pneumonia or acute extrinsic-allergic bronchiolar alveolitis (acute or sub-acute, 1 to  
6 months after exposure). After persistent exposure to low concentrations (e.g., after 6 months) chronic 
obstructive lung diseases or, rarely, lung fibrosis could develop. In a fatal case of TDI induced asthma, 
the autopsy showed findings identical to those found in status asthmaticus, like excessive production of 
mucus, overinflated lungs, extensive epithelia desquamation, thickening of bronchial wall due to sub 
epithelial  stroma  oedema,  and  increased  lymphocyte  infiltration  in  the  lamina  propria  [27,35].  In 
contrast  to  non-occupational  asthma,  the  bronchial  smooth  muscle  cells  were  hypertrophic  and 
disarrayed [35,36].  
Elevated levels of immune cells including eosinophils, CD45 positive cells (mostly mononuclear 
cells, only rare neutrophils) and mast cells were found in different compartments. [37-39]. Especially 
in  the  epithelium,  the  number  of  mast  cells  were  significantly  increased,  most  of  them  
degranulated [27]. 
Elevated levels of induced immune cells, especially CD4 but also CD8 positive T cells and the TH2 
cytokines  IL4  and  IL5  were  demonstrated  in  biopsies  and  sputum,  comparable  to  immunological 
processes seen in atopic asthma [8,22,40-42]. 
3. Pathogenesis of Isocyanate Asthma 
Several studies in humans have addressed the inflammatory process underlying isocyanate-induced 
asthma.  As  for  HMW-induced  occupational  asthma  the  pathogenetic  process  is  equal  to  an  IgE 
dependent  mechanism,  the  pathophysiology  of  OA  induced  by  low  molecular  weight  agents  as 
isocyanate is not well understood (e.g., [5, 6,40,41]).  
Elevated levels of induced immune cells, especially CD4 but also CD8 positive T cells and of 
different  cytokines like IL-1β, IL-4,  IL-5,  IL-6,  IL-15 and TNF-α were demonstrated in biopsies, 
broncho  alveolar  lavage  (BAL),  and  sputum  of  patients  with  isocyanate-induced  
asthma [8,39,40,42-44]. IFN-γ but no IL-5 or IL-13 expression was detected in human T-cell lines 
after exposure to HDI [45]. Other studies found a predominant activation of neutrophils [16,46,47] and 
an  increase  in  myeloperoxidase  and  IL-8  after  exposure  to  TDI  supporting  the  neutrophil  
recruitment [47,48]. An increased MMP-9 level in TDI exposed patients was found [49,50] associated Int. J. Environ. Res. Public Health 2011, 8                 
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with a decrease in MMP-7 expression and a regression of TH-2 type inflammation [50]. In late reaction 
after BAL Zocca et al. found increased levels of the chemotactic active leukotriene B4 in patients after 
exposure to TDI [51]. The role of neuropeptides in TDI induced hyperreactivity has been investigated 
so far in animal models [52,53]. Scheerens et al. demonstrated the role of sensory neuropeptides, 
especially tachykinins, in the development of airway hyperresponsiveness in a TDI induced mouse 
model [52] and Mapp et al. showed comparable effects in guinea pigs [53]. 
Taken together, these results show a heterogenic picture of a TH1 controlled inflammation process 
(TNF-α, IL-1, IL-8, INF-γ), but are also conform to a TH2 triggered allergic process (IL-4, IL-5, IL-6). 
These results mirror the controversial discussion, already above mentioned, about the impact of IgE 
antibodies in isocyanate induced asthma. Maybe, this is because heterogenic patient collectives were 
used in the investigation of isocyanate induced asthma, with differences in the type of isocyanate 
exposure (TDI, MDI, HDI, mixtures with other sensitizers), with different concentration and varying 
periods of incubation at the workplace, different time points for the investigation, and so forth.  
Incorporation  of  isocyanates  is  possible  by  pulmonary  inhalation  in  the  lungs,  or  skin  
exposure [12,54-56]. In particular isocyanates chemically react with NH2- and OH-groups of many 
proteins,  as  for  example  the  already  mentioned  tubulin,  albumin,  creatin-18,  and  glutathione  
(GSH) [11,21,28,42,57,58]. GSH is a protective molecule defending cells from oxidative stress. The 
reduction of functional GSH caused by binding of isocyanate could lead to increasing damage caused 
by oxidative exposure, resulting finally in apoptosis of bronchial epithelial cells. This could explain the 
loss of functional epithelium seen in isocyanate induced asthma. Additionally the isocyanate-GSH 
complex  is  transported  in  the  hole  body  during  the  detoxification  process  [22].  Furthermore,  the 
reaction  of  isocyanates  with  proteins  could  lead  to  the  formation  of  neo-antigens  inducing  an 
immunological reaction that might trigger an allergic asthma. Especially the binding to albumin seems 
to play a critical role in this process (Figure 1) [21,42,59,60]. 
Experiments in mice using high isocyanate doses demonstrate the presence of isocyanates and their 
derivatives  in  blood,  gastrointestinal  tract  and  in  lower  concentrations  in  other  organs.  Therefore, 
isocyanates are traceable throughout the body  and are eliminated in the urine.  In a monitoring of 
hydrolyzed urine samples for the presence of diamines, isocyanate exposure as low as 0.05 ppm could 
be detected in affected patients [10-12,61]. 
3.1. Influence of Genetic Factors in the Development of an Isocyanate Induced Asthma 
As only 5% to 10% of exposed workers develop isocyanate-related asthma [62], the question arose 
whether a genetic predisposition plays a substantial role in the development of the disease. Several 
groups  investigated  possible  candidate  genes  involved  in  isocyanate  metabolism.  Indeed,  several 
polymorphisms in the involved genes were detected, and significant correlations to the development of 
isocyanate induced asthma could be demonstrated. 
The  already  mentioned  role  of  glutathione  in  the  detoxification  process  of  isocyanate  strongly 
suggests that gene polymorphism coding for glutathione S-transferase (GST) play an important role in 
the  efficiency  of  the  elimination  of  isocyanates  from  the  body  and  therefore  might  predict  a 
susceptibility for the induction of an allergic reaction. Int. J. Environ. Res. Public Health 2011, 8                 
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Figure  1.  Predicted  mechanism  for  the  effects  of  isocyanate  in  the  development  of 
isocyanate induced asthma. The inhaled isocyanate or its derivates are absorbed by the 
bronchial epithelia cells, i.e., by binding to tubulin. This results in a local disturbance and 
impairment of cilia function or a detachment of bronchial epithelia cells. Glutathione S 
transferase mediates the detoxification process. If the capacity of GSH is exhausted, the 
free  isocyanate  can  bind  to  e.g.,  albumin.  This  isocyanate-albumin-complex  acts  as  a  
neo-epitope, that is recognized by the immune system, and is leading to an induction of an 
immunological process by activation of CD4+ cells. The following inflammation process 
and,  under  certain  circumstances,  an  additional  induction  of  IgE  antibodies  induce  the 
hypersensitivity reaction.  
 Int. J. Environ. Res. Public Health 2011, 8                 
 
 
3678 
In a study by Piirilä et al. 182 workers exposed to different isocyanates (HDI, TDI and MDI) were 
screened  for  polymorphisms  in  the  four  glutathione  S-transferase  (GST)  supergene  family  genes 
GSTM1, GSTM3, GSTP1 and GSTT1, and 109 workers showed signs of isocyanate induced asthma, 
while 73 did not. The loss of the GSTM1 gene (GSTM1 null) was shown to be associated with a  
1.89-fold  increased  risk  to  develop  isocyanate-induced  asthma.  In  addition,  patients  showing  the 
GSTM1 null genotype rarely generate IgE antibodies specific to isocyanate and show late reactions 
when tested in the specific inhalation challenge tests. The same late reaction was seen in patients with 
two alleles of the GSTM A genotype. In contrast, the genetic variant Val
105 of the GSTP1 type in the 
homogenous constellation (GSTP1 Val/Val) was associated with high level of IgE antibodies. The 
frequency of the GSTP1 Val
105/Val
105 genotype had been 9.2% in the patient group and 6.8% in the 
control group [62]. In contrast, Mapp et al. found a decreased risk for isocyanate-induced OA in the 
GSTP1 Val
105/Val
105 genotype. In this study, 131 patients (92 asthmatic patients, 39 asymptomatic 
workers), all exposed to TDI, were examined. The frequency of the GSTP1 Val
105/Val
105 genotype had 
been  6.5%  in  the  asthmatic  group  and  10.3%  in  the  non-asthmatic  group.  The  authors  found  an 
increase in the Val
105/Val
105 frequency up to 18.5% in the non-asthmatic group in individuals exposed 
to TDI for longer than 10 years, so the GSTP1 Val
105/Val
105 genotype showed a protective effect [63]. 
The same result was shown in another study performed by this group on 202 individuals [64]. Here it 
was  shown  that  the  GSTP1  Val
105/Val
105  genotype  was  associated  with  a  decreased  severity  of 
bronchial hyperresponsiveness and lower level of IgE antibodies defined by positive skin test. The 
authors critically discussed, as the number of individuals with GSTP1 Val
105/Val
105 genotype in this 
cohort was small (n = 13), the findings should be confirmed in larger study samples [64]. As already 
mentioned by Mapp et al., the contrary results in the studies of Mapp et al. and Piirilä et al. could be 
due to exposure to different isocyanates (TDI by Mapp et al., HDI, MDI and TDI by Piirilä et al.), 
differences in the definition of asthma, bronchial hyperresponsiveness and atopy in different centers, 
differences in the level and duration of exposure, or the small allele frequency in the cohorts. 
The  influence  of  these  polymorphisms  on  the  metabolism  of  the  detoxification  process  of 
isocyanate was investigated in studies done by Broberg et al. They measured the concentrations of TDI 
in the air and those of the TDI metabolites 2,4- and 2,6-toluenediamine (TDA) in urine samples and 
plasma, and determined the corresponding genotype. Those who were homozygotic for the GSTP1 
Val/Val allele had the highest regression of 2,4-TDA in plasma and therefore the highest concentration 
in urine when compared to GSTP1 Val/Ile and Ile/Ile. Similar results were obtained for 2,6-TDA. 
Different genotypes of the genes GSTM1, GSTP1, GSTT1, CYP1A1*2A and MPO also influenced the 
ratio between TDA in plasma and urine and therefore could predict a higher sensibility for isocyanate 
induced asthma in affected patients. In accordance with Mapp et al. [63] the authors found a tendency 
towards a protective effect of the GSTP1 Val
105/Val
105 genotype [65,66]. The mechanism by which 
this GSTP1 Val
105/Val
105 genotype variant influences the TDI metabolism is not known. Broberg et al. 
suggested a more effective conjugation of TDI to the GSTP1 Val
105/Val
105 variant, therefore reducing 
the concentration of unbound TDI in the plasma, which would then on the other hand result in lesser 
TDI-protein conjugates for allergic reactions [66]. 
IgE-independent isocyanate asthma could be caused by cell mediated immunity as described by 
Mapp et al. [24]. As a sign of this process many eosinophile granulocytes and activated T-cells are 
detectable in the bronchial mucosa. Important for the activation of T-cells is their interaction with Int. J. Environ. Res. Public Health 2011, 8                 
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antigen presenting cells (APCs). These cells (including dendritic cells, monocytes, macrophages and 
B-cells) present the antigen in association with the MHC II complex. This complex is encoded by the 
HLA (human leukocyte antigen) genes. Therefore, it is reasonable, that polymorphisms in the HLA 
genes influence the susceptibility for isocyanate asthma. In the publication of Mapp et al., 67 asthmatic 
patients and 27 non asthmatic, but also TDI exposed workers were included in the study. It was shown, 
that  the  HLA  class  II  genotypes  DQA1*0104  and  DQB*0503  are  significantly  overrepresented  in 
affected  persons,  whereas  the  genotypes  DQA1*0101  and  DQB1*0501  were  significantly 
overrepresented in exposed, but asymptomatic workers. On the other hand, the DRB1 genotype did not 
show any influence [67]. Interestingly, another investigation that involved the same polymorphisms in 
the HLA II genes by Rihs et al. found no correlation [68]. This discrepancy might be explained by the 
usage of different isocyanates (TDI, HDI, MDI) by Rihs instead of only one (TDI) used by Mapp, and 
by using healthy, not exposed blood donors as a control panel.  
In a recently published investigation Choi et al. aimed to clarify the influence of HLA I and HLA II 
gene  polymorphisms  on  the  risk  to  develop  diisocyanate-induced  occupational  asthma  [69].  Two 
hundred and fifty eight (258) people were enrolled in this study, 84 patients showed a diisocyanate 
induced asthma, 47 were exposed controls and 127 people served as non exposed controls. Here the 
haplotype  HLA  DRB1*1501-DQB1*0602-DPB1*0501  was  detected  significantly  more  often  in  
TDI-OA-Patients then in all other control patients. In addition, in patients with the DQB1*0402 allele 
IgE antibodies against TDI-albumin conjugates were more often found than in other groups. As these 
investigations  were  carried  out  in  a  Korean  collective,  it  is  not  clear  whether  the  results  can  be 
transcribed to a Caucasian collective, although the negative association for HLA class I genes has also 
been found in a Caucasian study cohort [70]. 
Beside HLA and GST gene polymorphism other genetic variations might be responsible for the 
susceptibility towards isocyanate-induced asthma. Kim et al. found an association of different genetic 
polymorphism  in  the  region  of  the  catenin  alpha  3  (CTNNA3)  gene  with  a  TDI  induced  asthma 
phenotype. In this investigation 84 patients with TDI induced asthma and 263 unexposed controls were 
analyzed in a microchip based SNP analysis [71]. CTNNA3 together with CTNNA1 are coding for  
α-catenin, a key molecule in the E-cadherin mediated cell-cell adhesion complex.  
The  collective  investigated  already  by  Piirilä  for GST  gene  polymorphisms  was  also  tested  for 
polymorphisms in the N-acetyltransferase (NAT) genes. In the NAT1 genotype (presumably a slow 
acetylating phenotype) the risk for the development of isocyanate-induced asthma was increased [72].  
Taking  these  demonstrated  genetic  polymorphisms,  which  could  be  associated  with  isocyanate 
induced asthma phenotype, into account, the question arose whether these genotypes play a role in the 
prevention and appraisal of occupational asthma. 
Bernstein  et  al.  investigated  the  effect  of  genetic  nucleotide  polymorphisms  of  interleukin  4 
receptor  alpha  (IL4RA),  IL-13,  and  CD14  in  isocyanate  exposed  workers  and  found  a  statistically 
significant  association  of  diisocyanate  asthma  with  the  IL4RA  (I50V),  IL13  (R110Q),  and  CD14 
(C159T) genotype combinations, but only in HDI exposed workers and not in those exposed to MDI or 
TDI. As discussed by the authors, the reason for this finding might be a statistical artifact due to the 
greater number of HDI-exposed subjects available in these studies [73,74]. Int. J. Environ. Res. Public Health 2011, 8                 
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4. Diagnosis of Occupational Isocyanate Induced Asthma 
In Germany, occupational diseases concerning contact with isocyanate (with the exception of skin 
effects) are summarized under the BK number 1315. At this time, approximately 50 new cases are 
accepted as occupationally-induced  every  year [12]. Due to the variety  of symptoms, the variable 
exposure including not only isocyanate, but also other solvents and the so far not complete known 
pathological  mechanisms,  the  clinical  diagnosis  is  still  not  an  easy  call  and  needs  a  multistage 
diagnostic approach (Table 1) [22,75]. 
Table 1. Diagnostic tools for the conformation of an occupational isocyanate associated 
asthma [22], modified. 
Diagnostic Approach  Result 
Medical examination 
Occupational anamnesis, exposure on the job 
 
Clinical verification of the 
asthmatic disease 
Confirmation of isocyanate 
exposure: characterization of the 
chemical substances 
Specification of the grade of 
exposure 
Physiological tests: 
Metacholine provocation test  
 
Spirometry 
PERFs (peak expiratory flow rate) 
 
SIC (specific inhalation challenge) 
 
Confirmation of the diagnose 
“asthma” and documentation of 
the occupational causation 
 
 
“Diagnostic reference standard”, 
characterization of the specific 
substance 
Immunological investigations 
Isocyanate specific IgE  
 
 
 
Isocyanate specific IgG 
 
Strong indicator for isocyanate 
induced asthma, not very 
sensitive 
 
Conformation of exposure 
towards isocyanate 
 
After the clinical confirmation of an asthmatic disease, the next step is to review the occupational 
history and the possible exposure to isocyanate or its derivatives. Thereafter, the specific inhalation 
challenge  test  (SIC)  is  the  reference  standard.  Here,  the  direct  correlation  to  the  asthma  inducing 
substance  could  be  resolved  [6,76].  Unfortunately,  this  test  needs  special  equipment  and  trained 
personal, and for this reason it is only available in a small number of laboratories [77]. The test is able 
to mimic the occupational load in a defined and nearly realistic way, but in some cases it could take up Int. J. Environ. Res. Public Health 2011, 8                 
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to several days, and even though it is time consuming and expensive, there have been reports of false 
negative results [76]. Especially after cessation of exposure to isocyanates the result of a first SIC may 
be negative. In a study of Sastre et al., 19 patients were challenged with TDI. Overall 16 showed an 
allergic reaction, three of them (16%) where false negative in the first SIC, but positive in a second  
SIC [78]. A recently published technical improvement might enhance the SIC test [79]. 
Other  diagnostic  possibilities  include  the  use  of  spirometry  and  the  evaluation  of  the  peak 
expiratory  flow  rate  (PERF).  In  both  cases  changes  could  be  evaluated  in  a  working  period  in 
comparison to a working free time period (weekend, holiday). The observation period should last at 
least four weeks, including one week free of occupational charge. During this period PERFs should be 
monitored four times a day [76]. When compared to the reference standard (SIC), the work attendant 
PERF showed a sensitivity of 64% and a specificity of 77% [6].  
Although the experimental findings concerning the significance of the presence of IgE-antibodies in 
isocyanate-induced  asthma  are  still  very  controversial,  the  immunological  detection  of  isocyanate 
specific IgE or IgG antibodies are an alternative diagnostic tool. A positive test for IgG antibodies 
clearly proves an isocyanate exposure [20,23,24] and the detection of IgE antibodies is a very high 
predictor for isocyanate-induced asthma [10,19,21]. Even though the sensitivity is low (21% to 55% 
are described, depending on the antigen used) the specificity is between 89% and 100% [76]. In a 
follow up study over 16 years Piirilä et al. showed a better clinical outcome for IgE positive patients 
when compared to IgE negative [80]. Because of these problems, the search for reliable biomarkers is 
ongoing, as nicely summarized in a recently published paper of Palikhe et al. [81]. 
5. Future Prospects 
Jobs associated with contact to isocyanates are steadily increasing. In the same way, the number of 
cases  showing  occupational  asthma  is  growing.  Therefore  the  diagnosis  of  occupational  induced 
Isocyanate asthma has a very high relevance due to the legal consequences. The so far described 
morphologic  subsumable  changes  could  be  seen  also  in  other  inflammatorily  or  toxically  induced 
damage  of  the  lung.  Therefore  there  are  no  specific  or  characteristic  morphologic  changes  for 
isocyanate-induced asthmatic disease known to date. Hence, beside the pathological and anatomical 
diagnostic, the clinical anamnesis must include data for the occupational burden of isocyanate in order 
to classify the manifested asthma as occupationally induced. 
In this context it has to be emphasized that only in rare cases histological specimens are available 
when isocyanate-induced asthma is diagnosed. Thus, it seems reasonable to enhance the sampling  
in order to search for isocyanate-induced  asthma specific  change(s) (on a morphological, immune 
histological  or  molecular  basis)  in  order  to  be  able  to  make  an  unequivocal  call  for  an  
occupational disease. 
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